Biomarin Pharmaceutical Inc (BMRN)
63.45
+0.89
(+1.42%)
USD |
NASDAQ |
Nov 21, 16:00
63.44
-0.01
(-0.02%)
After-Hours: 20:00
Biomarin Pharmaceutical Enterprise Value: 11.76B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
November 21, 2024 | 11.76B |
November 20, 2024 | 11.59B |
November 19, 2024 | 11.47B |
November 18, 2024 | 11.47B |
November 15, 2024 | 11.75B |
November 14, 2024 | 12.17B |
November 13, 2024 | 12.37B |
November 12, 2024 | 12.27B |
November 11, 2024 | 12.31B |
November 08, 2024 | 12.45B |
November 07, 2024 | 12.42B |
November 06, 2024 | 12.27B |
November 05, 2024 | 12.25B |
November 04, 2024 | 12.24B |
November 01, 2024 | 12.36B |
October 31, 2024 | 12.22B |
October 30, 2024 | 12.37B |
October 29, 2024 | 12.99B |
October 28, 2024 | 13.03B |
October 25, 2024 | 12.95B |
October 24, 2024 | 13.08B |
October 23, 2024 | 13.00B |
October 22, 2024 | 13.10B |
October 21, 2024 | 13.06B |
October 18, 2024 | 13.02B |
Date | Value |
---|---|
October 17, 2024 | 12.90B |
October 16, 2024 | 13.03B |
October 15, 2024 | 13.09B |
October 14, 2024 | 13.05B |
October 11, 2024 | 13.07B |
October 10, 2024 | 12.97B |
October 09, 2024 | 12.96B |
October 08, 2024 | 12.75B |
October 07, 2024 | 12.80B |
October 04, 2024 | 12.91B |
October 03, 2024 | 12.65B |
October 02, 2024 | 12.94B |
October 01, 2024 | 13.02B |
September 30, 2024 | 13.06B |
September 27, 2024 | 13.30B |
September 26, 2024 | 13.24B |
September 25, 2024 | 13.00B |
September 24, 2024 | 13.09B |
September 23, 2024 | 13.03B |
September 20, 2024 | 13.32B |
September 19, 2024 | 13.46B |
September 18, 2024 | 13.41B |
September 17, 2024 | 13.30B |
September 16, 2024 | 13.16B |
September 13, 2024 | 16.03B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.47B
Minimum
Nov 18 2024
23.80B
Maximum
Jul 20 2020
16.06B
Average
15.90B
Median
Jun 14 2024
Enterprise Value Benchmarks
Merck & Co Inc | 276.21B |
Bristol-Myers Squibb Co | 159.82B |
Pfizer Inc | 199.35B |
Biogen Inc | 27.62B |
Moderna Inc | 7.852B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 106.08M |
Revenue (Quarterly) | 745.74M |
Total Expenses (Quarterly) | 631.87M |
EPS Diluted (Quarterly) | 0.55 |
Gross Profit Margin (Quarterly) | 74.73% |
Profit Margin (Quarterly) | 14.22% |
Earnings Yield | 2.63% |
Operating Earnings Yield | 2.51% |
Normalized Earnings Yield | 2.566 |